SELLAS Life Sciences Group, Inc. Deferred Tax Liabilities, Gross
SELLAS Life Sciences Group, Inc. (SLS) had Deferred Tax Liabilities, Gross of $208.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-19
- 2025-12-31: Deferred Tax Liabilities, Gross $208.00K.
- 2024-12-31: Deferred Tax Liabilities, Gross $200.00K.
- 2023-12-31: Deferred Tax Liabilities, Gross $184.00K.
- 2022-12-31: Deferred Tax Liabilities, Gross $184.00K.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $208.00K 10-K · filed 2026-03-19 |
| 2024-12-31 | $200.00K 10-K · filed 2026-03-19 |
| 2023-12-31 | $184.00K 10-K · filed 2025-03-20 |
| 2022-12-31 | $184.00K 10-K · filed 2024-03-28 |
| 2021-12-31 | $152.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $1.39M 10-K · filed 2022-03-31 |
| 2019-12-31 | $1.27M 10-K · filed 2021-03-23 |
| 2018-12-31 | $1.78M 10-K · filed 2020-03-13 |
| 2017-12-31 | $3.44M 10-K · filed 2019-03-22 |
| 2016-12-31 | $5.66M 10-K · filed 2017-03-15 |
| 2015-12-31 | $5.42M 10-K · filed 2017-03-15 |
| 2014-12-31 | $5.05M 10-K/A · filed 2016-04-15 |
| 2013-12-31 | $5.05M 8-K · filed 2015-12-04 |
| 2012-12-31 | $5.05M 10-K · filed 2014-03-17 |
| 2011-12-31 | $5.05M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |